NCT03708328
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03708328
Title A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NZL | FRA | ESP | DNK

Facility Status City State Zip Country Details
Columbia Univ Med Ctr New York New York 10032 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Herlev Hospital Herlev 2730 Denmark Details
Rigshospitalet København Ø 2100 Denmark Details
Institut Bergonie Bordeaux 33076 France Details
Centre Leon Berard Lyon 69008 France Details
CHU Timone Marseille 13005 France Details
ICO Rene Gauducheau Saint-Herblain 44805 France Details
Auckland City Hospital Auckland 1023 New Zealand Details
Seoul National University Hospital Seoul 03080 South Korea Details
Severance Hospital, Yonsei University Health System Seoul 03722 South Korea Details
Asan Medical Center Seoul 05505 South Korea Details
Clinica Universitaria de Navarra Pamplona Navarre 31008 Spain Details
Vall d?Hebron Institute of Oncology (VHIO), Barcelona Barcelona 08035 Spain Details
Hospital Ramon y Cajal Madrid 28034 Spain Details
START Madrid-FJD, Hospital Fundacion Jimenez Diaz Madrid 28040 Spain Details
Hospital Clínico Universitario de Valencia Valencia 46010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field